STING1 and cancer: While here we employed a simplified model of an adoptive T cell therapy, these studies highlight the potential to leverage nanobody-STING agonist conjugates to enhance responses to multiple T cell-based immunotherapies, including autologous TIL therapy, CAR T cells, and cancer vaccines.